World Health Organization Issues Alert Over Critical Shortage of Weight-Loss Injections

Less than one in 10 individuals that would benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it releases its first recommendations on the drugs.

Considering in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to this class of drugs.

According to estimates, over two billion will be living with obesity by 2030 if no action is taken.

"The latest guidelines recognises that obesity is a chronic disease that can be managed with holistic and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing substantial weight, notes the body.

Skinny Jab Supply Crisis

Even in the current best projected outlook, the supply of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, per the WHO.

The advice urges nations and manufacturers to expand availability, by approaches such as licensing agreements.

Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in several nations in 2026.

How Obesity Jabs Operate

The injections imitate a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals reduce food intake.

Patients commonly start to lose weight after several weeks of starting on the regular doses.

Research indicates users may regain a significant portion within a year of halting the treatment, when their usual appetite return.

Being carrying excess weight raises your chance for developing diseases, including diabetes, heart disease, brain attack, and some cancers.

Excess weight affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.